FDA fast-tracks Genelux’s oncolytic virus-based ovarian cancer therapy

2 years ago 86

Olvi-Vec is currently being evaluated in a Phase III trial as a treatment for platinum- resistant/refractory ovarian cancer.

1. Homepage
2. Cancer
3. FDA fast-tracks Genelux’s oncolytic virus-based ovarian cancer therapy